APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Minimally Invasive Treatment of Lung Cancer

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Minimally Invasive Treatment of Lung Cancer Market Outlook and Growth Opportunities 2026

Report ID 17442690054 July 2026196 pages

Choose your research edition.

Industry ResearchMinimally Invasive Treatment of Lung Cancer Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Minimally Invasive Treatment of Lung Cancer Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Minimally Invasive Treatment of Lung Cancer Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Minimally Invasive Treatment of Lung Cancer Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Minimally Invasive Treatment of Lung Cancer Market Analysis and Forecast 2026-2032170 pages · $4,950 USD

Market perspective

The global Minimally Invasive Treatment of Lung Cancer market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Minimally Invasive Treatment of Lung Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Minimally Invasive Treatment of Lung Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Minimally Invasive Treatment of Lung Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Minimally Invasive Treatment of Lung Cancer market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Minimally Invasive Treatment of Lung Cancer market include Medtronic, LungCare, Broncus, Boston Scientific, Olympus, VISON Medical, Smith and Nephew, Nanjing MICRO-TECH and Intuitive Surgica, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Minimally Invasive Treatment of Lung Cancer market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Minimally Invasive Treatment of Lung Cancer and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Minimally Invasive Treatment of Lung Cancer revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Minimally Invasive Treatment of Lung Cancer market.

Minimally Invasive Treatment of Lung Cancer Segment by Company

Medtronic

LungCare

Broncus

Boston Scientific

Olympus

VISON Medical

Smith and Nephew

Nanjing MICRO-TECH

Intuitive Surgica

Auris Health

Angiodynamics

Minimally Invasive Treatment of Lung Cancer Segment by Type

Lung Tumor Ablation

Lung Tumor Embolization

Minimally Invasive Treatment of Lung Cancer Segment by Application

Hospitals

Ambulatory Surgical Centers

Minimally Invasive Treatment of Lung Cancer Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Minimally Invasive Treatment of Lung Cancer status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Minimally Invasive Treatment of Lung Cancer key companies, revenue, market share, and recent developments.

3. To split the Minimally Invasive Treatment of Lung Cancer breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Minimally Invasive Treatment of Lung Cancer market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Minimally Invasive Treatment of Lung Cancer significant trends, drivers, influence factors in global and regions.

6. To analyze Minimally Invasive Treatment of Lung Cancer competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Minimally Invasive Treatment of Lung Cancer market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Minimally Invasive Treatment of Lung Cancer and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Minimally Invasive Treatment of Lung Cancer.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Minimally Invasive Treatment of Lung Cancer industry.

Chapter 3: Detailed analysis of Minimally Invasive Treatment of Lung Cancer company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Minimally Invasive Treatment of Lung Cancer in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Minimally Invasive Treatment of Lung Cancer in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Minimally Invasive Treatment of Lung Cancer Industry Trends Table 2. Minimally Invasive Treatment of Lung Cancer Industry Drivers Table 3. Minimally Invasive Treatment of Lung Cancer Industry Opportunities and Challenges Table 4. Minimally Invasive Treatment of Lung Cancer Industry Restraints Table 5. Global Minimally Invasive Treatment of Lung Cancer Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Minimally Invasive Treatment of Lung Cancer Revenue Share by Company (2021-2026) Table 7. Global Minimally Invasive Treatment of Lung Cancer Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Minimally Invasive Treatment of Lung Cancer Key Company Manufacturing Base & Headquarters Table 9. Global Minimally Invasive Treatment of Lung Cancer Company, Product Type & Application Table 10. Global Minimally Invasive Treatment of Lung Cancer Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Minimally Invasive Treatment of Lung Cancer by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Lung Tumor Ablation Table 15. Significant Companies of Lung Tumor Embolization Table 16. Global Minimally Invasive Treatment of Lung Cancer Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Minimally Invasive Treatment of Lung Cancer Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Minimally Invasive Treatment of Lung Cancer Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Minimally Invasive Treatment of Lung Cancer Sales Value Share by Type (2021-2026) Table 20. Global Minimally Invasive Treatment of Lung Cancer Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Hospitals Table 22. Significant Companies of Ambulatory Surgical Centers Table 23. Global Minimally Invasive Treatment of Lung Cancer Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 24. Global Minimally Invasive Treatment of Lung Cancer Sales Value by Application (2021-2026) & (US$ Million) Table 25. Global Minimally Invasive Treatment of Lung Cancer Sales Value by Application (2027-2032) & (US$ Million) Table 26. Global Minimally Invasive Treatment of Lung Cancer Sales Value Share by Application (2021-2026) Table 27. Global Minimally Invasive Treatment of Lung Cancer Sales Value Share by Application (2027-2032) Table 28. Global Minimally Invasive Treatment of Lung Cancer Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Minimally Invasive Treatment of Lung Cancer Sales Value by Region (2021-2026) & (US$ Million) Table 30. Global Minimally Invasive Treatment of Lung Cancer Sales Value Share by Region (2021-2026) Table 31. Global Minimally Invasive Treatment of Lung Cancer Sales Value by Region (2027-2032) & (US$ Million) Table 32. Global Minimally Invasive Treatment of Lung Cancer Sales Value Share by Region (2027-2032) Table 33. Global Minimally Invasive Treatment of Lung Cancer Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Minimally Invasive Treatment of Lung Cancer Sales Value by Country (2021-2026) & (US$ Million) Table 35. Global Minimally Invasive Treatment of Lung Cancer Sales Value Market Share by Country (2021-2026) Table 36. Global Minimally Invasive Treatment of Lung Cancer Sales Value by Country (2027-2032) & (US$ Million) Table 37. Global Minimally Invasive Treatment of Lung Cancer Sales Value Market Share by Country (2027-2032) Table 38. Medtronic Company Information Table 39. Medtronic Business Overview Table 40. Medtronic Minimally Invasive Treatment of Lung Cancer Revenue (US$ Million) and Gross Margin (2021-2026) Table 41. Medtronic Minimally Invasive Treatment of Lung Cancer Product Portfolio Table 42. Medtronic Recent Development Table 43. LungCare Company Information Table 44. LungCare Business Overview Table 45. LungCare Minimally Invasive Treatment of Lung Cancer Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. LungCare Minimally Invasive Treatment of Lung Cancer Product Portfolio Table 47. LungCare Recent Development Table 48. Broncus Company Information Table 49. Broncus Business Overview Table 50. Broncus Minimally Invasive Treatment of Lung Cancer Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Broncus Minimally Invasive Treatment of Lung Cancer Product Portfolio Table 52. Broncus Recent Development Table 53. Boston Scientific Company Information Table 54. Boston Scientific Business Overview Table 55. Boston Scientific Minimally Invasive Treatment of Lung Cancer Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Boston Scientific Minimally Invasive Treatment of Lung Cancer Product Portfolio Table 57. Boston Scientific Recent Development Table 58. Olympus Company Information Table 59. Olympus Business Overview Table 60. Olympus Minimally Invasive Treatment of Lung Cancer Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Olympus Minimally Invasive Treatment of Lung Cancer Product Portfolio Table 62. Olympus Recent Development Table 63. VISON Medical Company Information Table 64. VISON Medical Business Overview Table 65. VISON Medical Minimally Invasive Treatment of Lung Cancer Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. VISON Medical Minimally Invasive Treatment of Lung Cancer Product Portfolio Table 67. VISON Medical Recent Development Table 68. Smith and Nephew Company Information Table 69. Smith and Nephew Business Overview Table 70. Smith and Nephew Minimally Invasive Treatment of Lung Cancer Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Smith and Nephew Minimally Invasive Treatment of Lung Cancer Product Portfolio Table 72. Smith and Nephew Recent Development Table 73. Nanjing MICRO-TECH Company Information Table 74. Nanjing MICRO-TECH Business Overview Table 75. Nanjing MICRO-TECH Minimally Invasive Treatment of Lung Cancer Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Nanjing MICRO-TECH Minimally Invasive Treatment of Lung Cancer Product Portfolio Table 77. Nanjing MICRO-TECH Recent Development Table 78. Intuitive Surgica Company Information Table 79. Intuitive Surgica Business Overview Table 80. Intuitive Surgica Minimally Invasive Treatment of Lung Cancer Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Intuitive Surgica Minimally Invasive Treatment of Lung Cancer Product Portfolio Table 82. Intuitive Surgica Recent Development Table 83. Auris Health Company Information Table 84. Auris Health Business Overview Table 85. Auris Health Minimally Invasive Treatment of Lung Cancer Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Auris Health Minimally Invasive Treatment of Lung Cancer Product Portfolio Table 87. Auris Health Recent Development Table 88. Angiodynamics Company Information Table 89. Angiodynamics Business Overview Table 90. Angiodynamics Minimally Invasive Treatment of Lung Cancer Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 91. Angiodynamics Minimally Invasive Treatment of Lung Cancer Product Portfolio Table 92. Angiodynamics Recent Development Table 93. Research Programs/Design for This Report Table 94. Authors List of This Report Table 95. Secondary Sources Table 96. Primary Sources List of Figures Figure 1. Minimally Invasive Treatment of Lung Cancer Product Image Figure 2. Global Minimally Invasive Treatment of Lung Cancer Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Minimally Invasive Treatment of Lung Cancer Market Size (2021-2032) & (US$ Million) Figure 4. Global Minimally Invasive Treatment of Lung Cancer Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Lung Tumor Ablation Image Figure 8. Lung Tumor Embolization Image Figure 9. Global Minimally Invasive Treatment of Lung Cancer Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Minimally Invasive Treatment of Lung Cancer Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Minimally Invasive Treatment of Lung Cancer Sales Value Share by Type (2021-2032) Figure 12. Hospitals Image Figure 13. Ambulatory Surgical Centers Image Figure 14. Global Minimally Invasive Treatment of Lung Cancer Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Minimally Invasive Treatment of Lung Cancer Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Minimally Invasive Treatment of Lung Cancer Sales Value Share by Application (2021-2032) Figure 17. Global Minimally Invasive Treatment of Lung Cancer Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global Minimally Invasive Treatment of Lung Cancer Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 19. North America Minimally Invasive Treatment of Lung Cancer Sales Value (2021-2032) & (US$ Million) Figure 20. North America Minimally Invasive Treatment of Lung Cancer Sales Value Share by Country (%), 2025 VS 2032 Figure 21. Europe Minimally Invasive Treatment of Lung Cancer Sales Value (2021-2032) & (US$ Million) Figure 22. Europe Minimally Invasive Treatment of Lung Cancer Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Asia-Pacific Minimally Invasive Treatment of Lung Cancer Sales Value (2021-2032) & (US$ Million) Figure 24. Asia-Pacific Minimally Invasive Treatment of Lung Cancer Sales Value Share by Country (%), 2025 VS 2032 Figure 25. South America Minimally Invasive Treatment of Lung Cancer Sales Value (2021-2032) & (US$ Million) Figure 26. South America Minimally Invasive Treatment of Lung Cancer Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Middle East & Africa Minimally Invasive Treatment of Lung Cancer Sales Value (2021-2032) & (US$ Million) Figure 28. Middle East & Africa Minimally Invasive Treatment of Lung Cancer Sales Value Share by Country (%), 2025 VS 2032 Figure 29. USA Minimally Invasive Treatment of Lung Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 30. USA Minimally Invasive Treatment of Lung Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 31. USA Minimally Invasive Treatment of Lung Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 32. Canada Minimally Invasive Treatment of Lung Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. Canada Minimally Invasive Treatment of Lung Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. Canada Minimally Invasive Treatment of Lung Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Mexico Minimally Invasive Treatment of Lung Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Mexico Minimally Invasive Treatment of Lung Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Mexico Minimally Invasive Treatment of Lung Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Germany Minimally Invasive Treatment of Lung Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Germany Minimally Invasive Treatment of Lung Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Germany Minimally Invasive Treatment of Lung Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. France Minimally Invasive Treatment of Lung Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. France Minimally Invasive Treatment of Lung Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. France Minimally Invasive Treatment of Lung Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. U.K. Minimally Invasive Treatment of Lung Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. U.K. Minimally Invasive Treatment of Lung Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. U.K. Minimally Invasive Treatment of Lung Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Italy Minimally Invasive Treatment of Lung Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Italy Minimally Invasive Treatment of Lung Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Italy Minimally Invasive Treatment of Lung Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Spain Minimally Invasive Treatment of Lung Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Spain Minimally Invasive Treatment of Lung Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Spain Minimally Invasive Treatment of Lung Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Russia Minimally Invasive Treatment of Lung Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Russia Minimally Invasive Treatment of Lung Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Russia Minimally Invasive Treatment of Lung Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Netherlands Minimally Invasive Treatment of Lung Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Netherlands Minimally Invasive Treatment of Lung Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Netherlands Minimally Invasive Treatment of Lung Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Nordic Countries Minimally Invasive Treatment of Lung Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Nordic Countries Minimally Invasive Treatment of Lung Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Nordic Countries Minimally Invasive Treatment of Lung Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. China Minimally Invasive Treatment of Lung Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. China Minimally Invasive Treatment of Lung Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. China Minimally Invasive Treatment of Lung Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Japan Minimally Invasive Treatment of Lung Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Japan Minimally Invasive Treatment of Lung Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Japan Minimally Invasive Treatment of Lung Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. South Korea Minimally Invasive Treatment of Lung Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. South Korea Minimally Invasive Treatment of Lung Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. South Korea Minimally Invasive Treatment of Lung Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. India Minimally Invasive Treatment of Lung Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. India Minimally Invasive Treatment of Lung Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. India Minimally Invasive Treatment of Lung Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Australia Minimally Invasive Treatment of Lung Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Australia Minimally Invasive Treatment of Lung Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Australia Minimally Invasive Treatment of Lung Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Southeast Asia Minimally Invasive Treatment of Lung Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Southeast Asia Minimally Invasive Treatment of Lung Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Southeast Asia Minimally Invasive Treatment of Lung Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Brazil Minimally Invasive Treatment of Lung Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Brazil Minimally Invasive Treatment of Lung Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Brazil Minimally Invasive Treatment of Lung Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Argentina Minimally Invasive Treatment of Lung Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Argentina Minimally Invasive Treatment of Lung Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Argentina Minimally Invasive Treatment of Lung Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Chile Minimally Invasive Treatment of Lung Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Chile Minimally Invasive Treatment of Lung Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Chile Minimally Invasive Treatment of Lung Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Colombia Minimally Invasive Treatment of Lung Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Colombia Minimally Invasive Treatment of Lung Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Colombia Minimally Invasive Treatment of Lung Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Peru Minimally Invasive Treatment of Lung Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Peru Minimally Invasive Treatment of Lung Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Peru Minimally Invasive Treatment of Lung Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Saudi Arabia Minimally Invasive Treatment of Lung Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Saudi Arabia Minimally Invasive Treatment of Lung Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Minimally Invasive Treatment of Lung Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Israel Minimally Invasive Treatment of Lung Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Israel Minimally Invasive Treatment of Lung Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Israel Minimally Invasive Treatment of Lung Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. UAE Minimally Invasive Treatment of Lung Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. UAE Minimally Invasive Treatment of Lung Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. UAE Minimally Invasive Treatment of Lung Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Turkey Minimally Invasive Treatment of Lung Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Turkey Minimally Invasive Treatment of Lung Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Turkey Minimally Invasive Treatment of Lung Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Iran Minimally Invasive Treatment of Lung Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Iran Minimally Invasive Treatment of Lung Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Iran Minimally Invasive Treatment of Lung Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Egypt Minimally Invasive Treatment of Lung Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Egypt Minimally Invasive Treatment of Lung Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Egypt Minimally Invasive Treatment of Lung Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Years Considered Figure 114. Research Process Figure 115. Key Executives Interviewed

Scope & coverage.

Types
  • Lung Tumor Ablation
  • Lung Tumor Embolization
Applications
  • Hospitals
  • Ambulatory Surgical Centers
Companies covered
  • Medtronic
  • LungCare
  • Broncus
  • Boston Scientific
  • Olympus
  • VISON Medical
  • Smith and Nephew
  • Nanjing MICRO-TECH
  • Intuitive Surgica
  • Auris Health
  • Angiodynamics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Minimally Invasive Treatment of Lung Cancer Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Minimally Invasive Treatment of Lung Cancer Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Minimally Invasive Treatment of Lung Cancer Market Dynamics
  1. 2.1 Minimally Invasive Treatment of Lung Cancer Industry Trends
  2. 2.2 Minimally Invasive Treatment of Lung Cancer Industry Drivers
  3. 2.3 Minimally Invasive Treatment of Lung Cancer Industry Opportunities and Challenges
  4. 2.4 Minimally Invasive Treatment of Lung Cancer Industry Restraints
3 Minimally Invasive Treatment of Lung Cancer Market by Company
  1. 3.1 Global Minimally Invasive Treatment of Lung Cancer Company Revenue Ranking in 2025
  2. 3.2 Global Minimally Invasive Treatment of Lung Cancer Revenue by Company (2021-2026)
  3. 3.3 Global Minimally Invasive Treatment of Lung Cancer Company Ranking (2024-2026)
  4. 3.4 Global Minimally Invasive Treatment of Lung Cancer Company Manufacturing Base and Headquarters
  5. 3.5 Global Minimally Invasive Treatment of Lung Cancer Company Product Type and Application
  6. 3.6 Global Minimally Invasive Treatment of Lung Cancer Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Minimally Invasive Treatment of Lung Cancer Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Minimally Invasive Treatment of Lung Cancer Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Minimally Invasive Treatment of Lung Cancer Market by Type
  1. 4.1 Minimally Invasive Treatment of Lung Cancer Type Introduction
  2. 4.1.1 Lung Tumor Ablation
  3. 4.1.2 Lung Tumor Embolization
  4. 4.2 Global Minimally Invasive Treatment of Lung Cancer Sales Value by Type
  5. 4.2.1 Global Minimally Invasive Treatment of Lung Cancer Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Minimally Invasive Treatment of Lung Cancer Sales Value by Type (2021-2032)
  7. 4.2.3 Global Minimally Invasive Treatment of Lung Cancer Sales Value Share by Type (2021-2032)
5 Minimally Invasive Treatment of Lung Cancer Market by Application
  1. 5.1 Minimally Invasive Treatment of Lung Cancer Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Ambulatory Surgical Centers
  4. 5.2 Global Minimally Invasive Treatment of Lung Cancer Sales Value by Application
  5. 5.2.1 Global Minimally Invasive Treatment of Lung Cancer Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Minimally Invasive Treatment of Lung Cancer Sales Value by Application (2021-2032)
  7. 5.2.3 Global Minimally Invasive Treatment of Lung Cancer Sales Value Share by Application (2021-2032)
6 Minimally Invasive Treatment of Lung Cancer Regional Value Analysis
  1. 6.1 Global Minimally Invasive Treatment of Lung Cancer Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Minimally Invasive Treatment of Lung Cancer Sales Value by Region (2021-2032)
  3. 6.2.1 Global Minimally Invasive Treatment of Lung Cancer Sales Value by Region: 2021-2026
  4. 6.2.2 Global Minimally Invasive Treatment of Lung Cancer Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Minimally Invasive Treatment of Lung Cancer Sales Value (2021-2032)
  7. 6.3.2 North America Minimally Invasive Treatment of Lung Cancer Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Minimally Invasive Treatment of Lung Cancer Sales Value (2021-2032)
  10. 6.4.2 Europe Minimally Invasive Treatment of Lung Cancer Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Minimally Invasive Treatment of Lung Cancer Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Minimally Invasive Treatment of Lung Cancer Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Minimally Invasive Treatment of Lung Cancer Sales Value (2021-2032)
  16. 6.6.2 South America Minimally Invasive Treatment of Lung Cancer Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Minimally Invasive Treatment of Lung Cancer Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Minimally Invasive Treatment of Lung Cancer Sales Value Share by Country, 2025 VS 2032
7 Minimally Invasive Treatment of Lung Cancer Country-level Value Analysis
  1. 7.1 Global Minimally Invasive Treatment of Lung Cancer Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Minimally Invasive Treatment of Lung Cancer Sales Value by Country (2021-2032)
  3. 7.2.1 Global Minimally Invasive Treatment of Lung Cancer Sales Value by Country (2021-2026)
  4. 7.2.2 Global Minimally Invasive Treatment of Lung Cancer Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Minimally Invasive Treatment of Lung Cancer Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Minimally Invasive Treatment of Lung Cancer Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Minimally Invasive Treatment of Lung Cancer Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Minimally Invasive Treatment of Lung Cancer Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Minimally Invasive Treatment of Lung Cancer Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Minimally Invasive Treatment of Lung Cancer Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Minimally Invasive Treatment of Lung Cancer Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Minimally Invasive Treatment of Lung Cancer Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Minimally Invasive Treatment of Lung Cancer Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Minimally Invasive Treatment of Lung Cancer Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Minimally Invasive Treatment of Lung Cancer Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Minimally Invasive Treatment of Lung Cancer Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Minimally Invasive Treatment of Lung Cancer Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Minimally Invasive Treatment of Lung Cancer Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Minimally Invasive Treatment of Lung Cancer Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Minimally Invasive Treatment of Lung Cancer Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Minimally Invasive Treatment of Lung Cancer Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Minimally Invasive Treatment of Lung Cancer Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Minimally Invasive Treatment of Lung Cancer Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Minimally Invasive Treatment of Lung Cancer Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Minimally Invasive Treatment of Lung Cancer Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Minimally Invasive Treatment of Lung Cancer Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Minimally Invasive Treatment of Lung Cancer Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Minimally Invasive Treatment of Lung Cancer Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Minimally Invasive Treatment of Lung Cancer Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Minimally Invasive Treatment of Lung Cancer Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Minimally Invasive Treatment of Lung Cancer Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Minimally Invasive Treatment of Lung Cancer Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Minimally Invasive Treatment of Lung Cancer Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Minimally Invasive Treatment of Lung Cancer Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Minimally Invasive Treatment of Lung Cancer Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Minimally Invasive Treatment of Lung Cancer Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Minimally Invasive Treatment of Lung Cancer Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Minimally Invasive Treatment of Lung Cancer Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Minimally Invasive Treatment of Lung Cancer Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Minimally Invasive Treatment of Lung Cancer Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Minimally Invasive Treatment of Lung Cancer Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Minimally Invasive Treatment of Lung Cancer Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Minimally Invasive Treatment of Lung Cancer Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Minimally Invasive Treatment of Lung Cancer Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Minimally Invasive Treatment of Lung Cancer Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Minimally Invasive Treatment of Lung Cancer Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Minimally Invasive Treatment of Lung Cancer Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Minimally Invasive Treatment of Lung Cancer Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Minimally Invasive Treatment of Lung Cancer Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Minimally Invasive Treatment of Lung Cancer Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Minimally Invasive Treatment of Lung Cancer Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Minimally Invasive Treatment of Lung Cancer Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Minimally Invasive Treatment of Lung Cancer Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Minimally Invasive Treatment of Lung Cancer Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Minimally Invasive Treatment of Lung Cancer Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Minimally Invasive Treatment of Lung Cancer Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Minimally Invasive Treatment of Lung Cancer Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Minimally Invasive Treatment of Lung Cancer Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Minimally Invasive Treatment of Lung Cancer Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Minimally Invasive Treatment of Lung Cancer Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Minimally Invasive Treatment of Lung Cancer Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Minimally Invasive Treatment of Lung Cancer Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Minimally Invasive Treatment of Lung Cancer Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Minimally Invasive Treatment of Lung Cancer Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Minimally Invasive Treatment of Lung Cancer Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Minimally Invasive Treatment of Lung Cancer Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Minimally Invasive Treatment of Lung Cancer Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Minimally Invasive Treatment of Lung Cancer Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Minimally Invasive Treatment of Lung Cancer Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Minimally Invasive Treatment of Lung Cancer Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Minimally Invasive Treatment of Lung Cancer Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Minimally Invasive Treatment of Lung Cancer Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Minimally Invasive Treatment of Lung Cancer Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Minimally Invasive Treatment of Lung Cancer Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Minimally Invasive Treatment of Lung Cancer Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Minimally Invasive Treatment of Lung Cancer Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Minimally Invasive Treatment of Lung Cancer Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Minimally Invasive Treatment of Lung Cancer Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Minimally Invasive Treatment of Lung Cancer Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Minimally Invasive Treatment of Lung Cancer Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Minimally Invasive Treatment of Lung Cancer Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Minimally Invasive Treatment of Lung Cancer Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Minimally Invasive Treatment of Lung Cancer Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Minimally Invasive Treatment of Lung Cancer Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Minimally Invasive Treatment of Lung Cancer Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Minimally Invasive Treatment of Lung Cancer Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Minimally Invasive Treatment of Lung Cancer Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Minimally Invasive Treatment of Lung Cancer Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Medtronic
  2. 8.1.1 Medtronic Company Information
  3. 8.1.2 Medtronic Business Overview
  4. 8.1.3 Medtronic Minimally Invasive Treatment of Lung Cancer Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Medtronic Minimally Invasive Treatment of Lung Cancer Product Portfolio
  6. 8.1.5 Medtronic Recent Developments
  7. 8.2 LungCare
  8. 8.2.1 LungCare Company Information
  9. 8.2.2 LungCare Business Overview
  10. 8.2.3 LungCare Minimally Invasive Treatment of Lung Cancer Revenue and Gross Margin (2021-2026)
  11. 8.2.4 LungCare Minimally Invasive Treatment of Lung Cancer Product Portfolio
  12. 8.2.5 LungCare Recent Developments
  13. 8.3 Broncus
  14. 8.3.1 Broncus Company Information
  15. 8.3.2 Broncus Business Overview
  16. 8.3.3 Broncus Minimally Invasive Treatment of Lung Cancer Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Broncus Minimally Invasive Treatment of Lung Cancer Product Portfolio
  18. 8.3.5 Broncus Recent Developments
  19. 8.4 Boston Scientific
  20. 8.4.1 Boston Scientific Company Information
  21. 8.4.2 Boston Scientific Business Overview
  22. 8.4.3 Boston Scientific Minimally Invasive Treatment of Lung Cancer Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Boston Scientific Minimally Invasive Treatment of Lung Cancer Product Portfolio
  24. 8.4.5 Boston Scientific Recent Developments
  25. 8.5 Olympus
  26. 8.5.1 Olympus Company Information
  27. 8.5.2 Olympus Business Overview
  28. 8.5.3 Olympus Minimally Invasive Treatment of Lung Cancer Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Olympus Minimally Invasive Treatment of Lung Cancer Product Portfolio
  30. 8.5.5 Olympus Recent Developments
  31. 8.6 VISON Medical
  32. 8.6.1 VISON Medical Company Information
  33. 8.6.2 VISON Medical Business Overview
  34. 8.6.3 VISON Medical Minimally Invasive Treatment of Lung Cancer Revenue and Gross Margin (2021-2026)
  35. 8.6.4 VISON Medical Minimally Invasive Treatment of Lung Cancer Product Portfolio
  36. 8.6.5 VISON Medical Recent Developments
  37. 8.7 Smith and Nephew
  38. 8.7.1 Smith and Nephew Company Information
  39. 8.7.2 Smith and Nephew Business Overview
  40. 8.7.3 Smith and Nephew Minimally Invasive Treatment of Lung Cancer Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Smith and Nephew Minimally Invasive Treatment of Lung Cancer Product Portfolio
  42. 8.7.5 Smith and Nephew Recent Developments
  43. 8.8 Nanjing MICRO-TECH
  44. 8.8.1 Nanjing MICRO-TECH Company Information
  45. 8.8.2 Nanjing MICRO-TECH Business Overview
  46. 8.8.3 Nanjing MICRO-TECH Minimally Invasive Treatment of Lung Cancer Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Nanjing MICRO-TECH Minimally Invasive Treatment of Lung Cancer Product Portfolio
  48. 8.8.5 Nanjing MICRO-TECH Recent Developments
  49. 8.9 Intuitive Surgica
  50. 8.9.1 Intuitive Surgica Company Information
  51. 8.9.2 Intuitive Surgica Business Overview
  52. 8.9.3 Intuitive Surgica Minimally Invasive Treatment of Lung Cancer Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Intuitive Surgica Minimally Invasive Treatment of Lung Cancer Product Portfolio
  54. 8.9.5 Intuitive Surgica Recent Developments
  55. 8.10 Auris Health
  56. 8.10.1 Auris Health Company Information
  57. 8.10.2 Auris Health Business Overview
  58. 8.10.3 Auris Health Minimally Invasive Treatment of Lung Cancer Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Auris Health Minimally Invasive Treatment of Lung Cancer Product Portfolio
  60. 8.10.5 Auris Health Recent Developments
  61. 8.11 Angiodynamics
  62. 8.11.1 Angiodynamics Company Information
  63. 8.11.2 Angiodynamics Business Overview
  64. 8.11.3 Angiodynamics Minimally Invasive Treatment of Lung Cancer Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Angiodynamics Minimally Invasive Treatment of Lung Cancer Product Portfolio
  66. 8.11.5 Angiodynamics Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst